After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals Incorporated (VRTX) is a trending stock: Facts to know before betting on it
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended ...
Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received ...
Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...
Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...
Each year, around 80 million Americans are prescribed a medicine for moderate to severe pain. Journavx is the first new type of painkiller approved in more than 20 years. It prevents pain signals from ...
Zacks Investment Research on MSN
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...
Side visibility is critical to some aspects of job site safety, be it parked at an intersection of pulling across traffic while towing a trailer. Great strobes are lifesavers. Only 7/8″ in height, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback